Colin Reisner

Biography

"Colin Reisner joined Pearl Therapeutics in October 2007, in the capacity of Chief Medical Officer and Executive Vice President of Clinical Development and Medical Affairs. Dr. Reisner is responsible for all of Pearl’s clinical development activities including advancing Pearl’s lead program, a combination bronchodilator, through regulatory submission. Dr. Reisner has significant experience in the development and commercialization of inhaled respiratory products. Prior to Pearl, he was Executive Director for Global Respiratory Development at Novartis responsible for both clinical development and shaping Novartis’ global strategy for respiratory products. Earlier at Novartis he was the Global Brand Medical Director for Xolair®, the first biologic agent approved for asthma. Prior to Novartis, Dr. Reisner served as Senior Director in the Respiratory Division at GlaxoSmithKline. There he played a key role in the development of market-leading inhaled respiratory products, focusing on Advair® in COPD, and on pediatric drug development. Dr. Reisner began his career in the pharmaceutical industry at Boehringer Ingelheim and worked on a wide variety of programs including Combivent® and on the Respimat® device. Dr. Reisner graduated from the University of Witwatersrand Medical School in South Africa. He completed his training in Internal Medicine followed by fellowship training in Allergy and Immunology at National Jewish, Denver, Colorado, and was an assistant consulting professor of Allergy and Immunology at Yale University, and also at Duke University. Dr. Reisner is a Diplomat of the American Board of Internal Medicine and the American Board of Allergy and Immunology."

Research Interest

Clinical Development and Medical Affairs